Development of fibrosis and impairment of lung function in patients with a new coronavirus disease

The aim: review scientific research to find out whether the new coronavirus infection (NCI) causes fibrotic changes in lungs and, if any, how long they persist and functional disorders of respiratory system accompany them. Disruption state patients with severe novel disease (COVID-19) is still seen 6 months after completion inpatient treatment. High-resolution computed tomography (HRCT) demonstrates persistent pathological lungs, some which are fibrosis-like. Pathomorphological features COVID-19 course, as well ability virus activate connective tissue growth factor (CTGF) enhance signaling transforming factor-beta (TGF-β), can contribute lung fibrosis. Increased titers antinuclear autoantibodies specific indirectly reveal dysregulation immune response leading progression organizing pneumonia tissue. These increased also indicate need prescribe immunosuppressive antifibrotic drugs. Researchers considering possibility including drugs combination therapy for early stages treatment risk factors developing pulmonary However, further monitoring determination role required. Sometimes develop severe, irreversible disease, transplantation only option. Conclusion. There no unequivocal opinion among researchers concerning clinical significance prognosis so far, a reason studies.